Life Biosciences
Last verified 2026-05-25. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $150.0Mattributed |
|---|---|
| Latest round | series-d+, $80.0M, 2026-04-01attributed |
| Founded | 2016 |
| Headquarters | Boston, United States |
| Industry | bio |
| Stage | series-b+ |
| Website | lifebiosciences.com |
Life Biosciences develops partial epigenetic reprogramming therapies that revert aged cells to a younger functional state for age-related disease. It targets patients with optic neuropathies and liver disease first, expanding to broader aging conditions. Lead candidate ER-100 cleared FDA investigational use in January 2026, targeting causes rather than symptoms.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-04-01 | series-d+ | $80.0M | undisclosed |
Detected tech stack
unknown
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series D+, $80.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $150.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | lifebiosciences.com, read 2026-05-25 |
| Description | self-reported | lifebiosciences.com, read 2026-05-25 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.